Table IV.
Clinical characteristics and pathological features of patients.
| Variable | n | % |
|---|---|---|
| HER-2/neu | ||
| 0 | 38 | 45.2 |
| 1+ | 20 | 23.8 |
| 2+ | 9 | 10.7 |
| 3+ | 17 | 20.2 |
| Estrogen/progesterone receptor status | ||
| Positive/positive (+/+) | 78 | 92.9 |
| Positive/negative (+/−) | 6 | 7.1 |
| Recurrence | ||
| Positive | 15 | 17.9 |
| Negative | 69 | 82.1 |
| TNM stage | ||
| I | 10 | 11.9 |
| II | 46 | 54.8 |
| III | 14 | 16.7 |
| IV | 14 | 16.7 |
| Lymph node involvement | ||
| Positive | 66 | 78.6 |
| Negative | 18 | 21.4 |
| Metastasis | ||
| Negative | 69 | 82.1 |
| Bone | 11 | 13.1 |
| Liver | 3 | 3.6 |
| Bone and liver | 1 | 1.2 |
| History of resection | ||
| Positive | 82 | 97.6 |
| Negative | 2 | 2.4 |
| Type of resection | ||
| Radical mastectomy | 1 | 1.2 |
| Modified radical mastectomy | 49 | 59.8 |
| Conservative | 32 | 39.0 |
| Previous chemotherapy | ||
| Positive | 80 | 95.2 |
| Negative | 4 | 4.8 |
| Type of chemotherapy | ||
| Adjuvant | 70 | 87.5 |
| Neo-adjuvant | 10 | 12.5 |
| Concurrent diseases | ||
| Positive | 37 | 44.1 |
| Negative | 47 | 55.9 |
| History of radiotherapy | ||
| Positive | 71 | 84.5 |
| Negative | 13 | 15.5 |
| History of oral contraceptive pill use | ||
| Positive | 44 | 52.4 |
| Negative | 40 | 47.6 |
HER-2/neu expression status was based on results of immunohistochemistry: 0 or 1+ (negative), 2+ (borderline) or 3+ (positive). TNM staging was according to the American Joint Committee on Cancer staging manual (7th edition) (45).